Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 73

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 73
---
, which may be material, if the price of our Ordinary Shares declines after this offering or if such investors purchase
shares of our Ordinary Shares prior to any price decline.

<div align='center'>47</div>

If our operating and financial performance in any given period does not meet any guidance that we provide to the public, the market price of our Ordinary Shares may decline.

We may, but are not obligated
to, provide public guidance on our expected operating and financial results for future periods. Any such guidance will be comprised of
forward-looking statements subject to the risks and uncertainties described in this prospectus and in our other public filings and public
statements. Our actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic
uncertainty. If, in the future, our operating or financial results for a particular period do not meet any guidance we provide or the
expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our Ordinary Shares may decline.
Even if we do issue public guidance, there can be no assurance that we will continue to do so in the future.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our shares, the price of our shares could decline.

The trading market for our
securities will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not
currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us,
the trading price of our shares could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business
downgrade their evaluations of our shares, the price of our shares could decline. If one or more of these analysts cease to cover our
shares, we could lose visibility in the market for our shares, which in turn could cause our share price to decline.

Raising additional capital would cause dilution to our existing shareholders, and may adversely affect the rights of existing shareholders.

We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations, and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity (such as this offering) or otherwise including through convertible
debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect
your rights as a shareholder. Future sales of our